MRD & Molecular Residual Disease 1 article

MRD & Molecular Residual Disease examines evidence of disease that remains after treatment but is not necessarily visible through routine clinical assessment. In hematologic malignancies this may involve measurable or minimal residual disease assays, while solid-tumor coverage can include molecular residual disease detected through ctDNA. The section focuses on post-treatment detection, assay sensitivity, recurrence risk and clinical utility, keeping broader liquid-biopsy profiling and screening in separate categories.